兒童睡眠健康

cystic fibrosis lungs
Pediatric Sleep Health Sleep Pharmaceuticals

FDA Grants SPIRO-2101 CF Treatment Orphan Drug and Rare Pediatric Disease Designations 

Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis. SPIRO-2101, an inhaled […]